Investigating the role of Ly6K in breast cancer treatment
Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer
This study is looking at a protein called Ly6K to see how it affects triple negative breast cancer and is working on new treatments that could help slow down the cancer's growth for patients dealing with this type of breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10453713 on NIH RePORTER |
What this research studies
This research focuses on understanding how the protein Ly6K contributes to the progression of triple negative breast cancer (TNBC) and its potential as a therapeutic target. The researchers have found that higher levels of Ly6K are linked to worse outcomes in TNBC patients. They are developing small drug-like molecules that specifically target Ly6K, aiming to inhibit tumor growth by blocking certain signaling pathways involved in cancer progression. By validating these treatments in humanized models, the study seeks to provide new options for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with other types of breast cancer or those whose tumors do not express Ly6K may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with triple negative breast cancer, improving treatment outcomes.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Upadhyay, Geeta — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Upadhyay, Geeta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.